biologic medicines

Market Access

China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline.

News

Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.